IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

•			• •		_
ln	re	app	licat	ion	ot

Masahiro TERADA et al.

Mail Stop: PCT

Serial No. NEW

Attorney Docket No. 2006 1253A

Filed August 17, 2006

GUANIDINE COMPOUND AND ASYMMETRIC REACTION USING THE SAME [Corresponding to PCT/JP2005/001943 Filed February 9, 2005]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

	[X]	each U.S. Patent and U.S. Patent application publication;			
		each reference previously cited in the international application PCT/; and/or			
	[]	each reference previously cited in prior parent application Serial No.			
1a.	[X] This Information Disclosure Statement is submitted:				
	within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or				

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. [] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 2. It is hereby certified
 - a. [] that each item of information contained in this Information Disclosure

 Statement was first cited in any communication from a foreign patent office in a

 counterpart foreign application not more than three months prior to the filing of
 the Statement, or
 - b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

IAPS REC'D PCT/PTO 17 AUG 2006

3. []	Consideration of the following list of additional information (including any copending or
	abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4.		For each non-English language reference listed on the attached form PTO-1449, reference is made to:				
	a. []	a full or partial English language translation submitted herewith,				
	b. []	a foreign patent office search report (in the English language) submitted herewith,				
	c. []	the concise explanation contained in the specification of the present application at page,				
	d. []	the concise explanation set forth in the attached English language abstract,				
	e. []	the concise explanation set forth below or on a separate sheet attached to the				

5. [X] A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Masahiro TERADA et al.

Rv

Warren M. Cheek, (r.) Registration No. 33,367

Attorney for Applicants

WMC/dlk Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 August 17, 2006

reference:

				28 P. 10 1 HA 1 1 1 1	<u> </u>	17	AUG 2006
Sheet 1 of 1 INFORMA			ATION DISCLOSURE STATEMENT			nou Zoug	
FORM PTO 1449 (n		TMENT OF COMMERCI	E	ATTY DOCKET NO. 2006_1253A	SERIAL NEV	0/589	814
PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S)			APPLICANT Masahiro TERADA et al.				
		eral shèets if necessary) ed to PTO: August 17, 20	006	FILING DATE August 17, 2006		GROUP	
		T	U	S. PATENT DOCUMENTS			Υ
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,340,753	1/2002	Maruoka			Corresponds to AE
e desir	AB	4,833,245	5/1989	Bruderer et al.			Corresponds to AF
	AC						
			FOR	REIGN PATENT DOCUMENTS			·
· · ·		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AD	2000-198774	7/2000	JP			Abstract
	AE	2001-048866	2/2001	JP			Abstract
	AF	61-161266	7/1986	JP			х
	AG						
	АН						
		OTHER	DOCUMENT(S)	(Including Author, Title, Date, Pertine	ent Pages, Etc.)		
	Al	H. Y. Aboul-Enein et al., "Synthesis and Biological Activity of Dibenz[c,e]Azepines", Drug Design and Delivery, Vol. 4, No. 1, pp. 27-33, 1989.					
	AJ	R. Chinchilla et al., "Enantiomerically Pure Guanidine-Catalysed Asymmetric Nitroaldol Reaction", Tetrahedron: Asymmetry, Vol. 5, No. 7, pp. 1393-1402, 1994.					
	AK	M. T. Allingham et al., "Synthesis and Applications of C ₂ -Symmetric Guanidine Bases", Tetrahedron Letters, Vol. 44, No. 48, pp. 8677-8680, 2003.					
	AL	T. Ooi et al., "Design of N-Spiro C ₂ -Symmetric Chiral Quanternary Ammonium Bromides as Novel Chiral Phase- Transfer Catalysts: Synthesis and Application to Practical Asymmetric Synthesis of α-Amino Acids", JACS Articles, No. 125, No. 17, pp. 5139-5151, 2003.					
	АМ			nantioselective Synthesis of 22, No. 21, pp. 5228-5229, 20		Amino Acids by	/ Chiral Phase-

ΑN

EXAMINER

T. Ooi et al., "Molecular Design of a C_2 -Symmetric Chiral Phase-Transfer Catalyst for Practical Asymmetric Synthesis of α -Amino Acids", JACS, Vol. 121, No. 27, pp. 6519-6520, 1999.

DATE CONSIDERED